Pharmaceutical R&D

A solid R&D platform is the foundation of a successful pharmaceutical program. Government and industry clients at all stages of the drug discovery cycle turn to SRI Biosciences to rapidly identify and optimize new drug leads and move them toward preclinical development.

SRI Biosciences applies its more than 40 years of experience to solve challenges in formulation, drug delivery development, and the characterization of small molecule drugs and biologics.

SRI's approach to drug formulation is customized to the needs of clients and partners. Services range from the preparation of dose formulations for preclinical in vitro and in vivo safety studies, to the design of finished product dosage forms for clinical trials.

SRI also provides pharmaceutical R&D support and services in these areas:

Our pharmaceutical R&D services meet worldwide stringent regulatory requirements. SRI studies are conducted under current Good Laboratory Practice (GLP) and Good Manufacturing Practice (cGMP) regulations.

Projects

bioscience workers in a lab

SRI is conducting preclinical development of treatments for diseases such as tuberculosis, West Nile virus, hepatitis, and biodefense pathogens and toxins.

scientist looking through a microscope

For the National Institute of Mental Health (NIMH), SRI performs preclinical safety and pharmacokinetics studies for brain imaging agents and drugs to treat mental illnesses.

scientist with a computer model of a molecular structure

SRI is identifying candidates for advanced therapies in multiple disease areas by developing compounds from synthetically optimized, natural dietary products.

scientist checking a batch of vaccines

SRI has patented a novel approach to vaccine delivery that is safe for pediatric use, eliminating the need for painful injections.

scientist working with a chelating agent

A new oral version of a known chelating agent can defend against mass radiation exposure in a terrorist attack.

hand holding a petri dish of bacterial culture up to the light

Vitamin A deficiency causes susceptibility — especially in children — to diarrhea-causing infections, which lead to millions of deaths each year. SRI is developing a probiotic that produces the vitamin.

Products + Solutions

researchers in lab coats working at a lab table

SRI researchers have developed a novel steroidal compound, SR16388, which very selectively binds to and inhibits ERRalpha. This drug also regulates tumor energy metabolism by strongly inhibiting the protein HIF-1alpha, which promotes tumor cell survival in low-oxygen conditions.

Press Releases

building in Michigan

The Michigan Strategic Fund approved the Center of Innovation designation and $5 million in initial funding for SRI Biosciences to open a Phase 1 clinical trial facility that will address unmet medical needs.

microscopic view of the HIV virus

Researchers are developing and testing a topical microbicide gel for drug delivery. The innovative formulation will be a combination therapy against human immunodeficiency virus (HIV) and herpes simplex virus type 2 (HSV-2) infections in women.

Researchers at SRI are developing a new Multiple Sclerosis drug that can be taken by mouth. It will be more convenient than current treatments, which require frequent hospital visits for injections or intravenous infusions.

researchers in SRI  lab

SRI International has been awarded a contract worth up to $100.5 million over 10 years from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH)

Jia-Hwa Fang

Jia-Hwa Fang, Ph.D., has joined SRI Biosciences as Director of Clinical Manufacturing. In this new role, he will lead a team to transfer and scale-up R&D, Good Laboratory Practice (GLP), and pilot formulations for early stage clinical trial materials.

DNA gyrase

In research at SRI International, scientists evaluating new drug targets against tuberculosis (TB) recently validated the preclinical effectiveness of a target that could rapidly eliminate infections and potentially shorten treatment time.

SRI International has been awarded two National Cancer Institute (NCI) preclinical service contracts totaling $14.3 million. The contracts provide SRI up to $11.7 million for toxicology studies and an additional $2.6 million for pharmacology and pharmacokinetics studies.

SRI Shenandoah Valley has authorized the build-out of the remaining space in its 40,000 square foot state-of-the-art research facility in the Rockingham Center for Research and Technology.

SRI In the News

Fighting Deadly Parasitic Infections with a UV Flashlight

This video interview with Ellen Beaulieu, a medicinal chemist at SRI International, shows how SRI researchers are using fluorescent dyes and a simple ultraviolet flashlight to create a test that can detect parasitic infections in human beings.

Jon Mirsalis
Fighting the War on Infectious Diseases: An Interview with SRI's Jon Mirsalis

Jon Mirsalis of SRI Biosciences describes how SRI researchers are developing drugs to fight infectious diseases like HIV, malaria, tuberculosis and the flu. Over the years, SRI has helped save thousands of lives by moving drugs from the early discovery stage into human clinical trials.